ArticleFrontiers in medicine2025
Gastric juice MicroRNAs as biomarkers for functional dyspepsia: an observational case-control study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: MicroRNAs (miRNAs, miRs) are stable RNA molecules that regulate gene expression and hold promise as biomarkers. Functional dyspepsia (FD), a complex gastrointestinal disorder, is characterized by motility dysfunction, visceral hypersensitivity, and gut microbiome alterations. Given the limitations of current diagnostic markers, miRNAs may offer novel insights for diagnosis and risk stratification. Methods: We conducted an observational case-control study involving 28 FD patients (14 with epigastric pain syndrome [EPS], 14 with postprandial distress syndrome [PDS]) and 22 healthy controls (HC). All subjects underwent gastroscopy with gastric juice collection. Quantitative real-time PCR was used to measure levels of selected miRNAs (miR-21-5p, miR-155-5p, miR-203a) in gastric fluid, with miR-16 and U6 as endogenous controls. Fold-change in miRNA expression was calculated. We compared miRNA levels between groups and between FD subtypes and assessed correlations with symptom severity (using the Functional Dyspepsia Symptom Diary scores). Statistical significance was determined by non-parametric tests, with Results: Gastric juice miR-21-5p was significantly elevated in FD patients compared to controls (FD: 19.98 ± 91.56 fold-change vs. HC: 2.63 ± 3.30 fold-change Conclusion: FD patients might have altered gastric juice miRNA profiles, notably an upregulation of miR-21, and distinctive differences between PDS and EPS subtypes. The PDS subtype is characterized by a high-miR-21 and miR-155 and low-miR-203 signature, whereas the opposite pattern is observed in EPS. These miRNA alterations align with the symptomatology of FD subtypes and may reflect underlying pathophysiological differences. Gastric juice miRNAs could serve as minimally invasive biomarkers for FD, aiding in differentiating functional subgroups and potentially guiding targeted therapies. Further studies are warranted to confirm this findings and establish their diagnostic utility and role in FD pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.